The Filing Desk

Agenus

AGEN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

AGEN · Last close · November 19, 2026
$6.14
Value Agenus yourself

Agenus' revenue rose 10.4% to $114 million in fiscal 2025. Its operating margin was −17.7%, up from −116.4% a year earlier. Free cash flow was −$77 million. The diluted share count rose 38.5%.

AGENUS INC Latest fiscal year ended December 31, 2025 10-K filed March 16, 2026 · 0001193125-26-108632 Updated
Revenue
$114M
10.4%
Operating margin
−17.7%
98.8 pts
Net income
−$3M
 
Free cash flow
−$77M
 
Return on equity
—
 
Market cap
$511M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (50-for-1), so every year is on today's share basis. The SEC's structured data gives diluted share counts for fiscal 2017 to 2020 in thousands without saying so; they are shown here in millions, which makes net income per share match the reported earnings per share.

Charts show fiscal years, from the 10-K filings.

What Agenus does

Agenus is a clinical-stage biotechnology company, which means it has no approved products yet. It develops immunotherapies for cancer and infectious disease. Immunotherapies are treatments that help the body's immune system fight disease.

Its main business is immuno-oncology, using antibodies to activate the immune system against tumors. Its lead program is botensilimab, alone and combined with balstilimab. With the Canadian Cancer Trials Group, it is running a global Phase 3 trial of the combination against best supportive care in refractory colorectal cancer. In France, a national access program lets eligible patients get the combination in hospitals, reimbursed by the national health system.

After a strategic realignment announced in December 2024, Agenus put its resources behind the botensilimab and balstilimab program and paused some other early work while it looks at partnering and funding. It also holds an equity investment in MiNK Therapeutics and a majority stake in SaponiQx, a vaccine adjuvant business. Its stock trades on the Nasdaq Capital Market.

Its biggest risks, as it describes them

  • Net losses so far and expected in the future, and a need for additional financing to finish development.
  • Its auditor's report raises doubt about its ability to continue as a going concern.
  • Its business depends heavily on the success of botensilimab and its combination therapy programs.
  • Trials could show serious side effects or too little benefit, and enrolling patients could prove difficult.
From Agenus's annual report on Form 10-K, filed March 16, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Agenus lost money in fiscal 2025: a net loss of $3 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments30719376403
Debt incl. finance leases1413133845
Net debt (negative means net cash)−293−180−63−242
Net debt to EBITDA−9.0x————
Debt to equity0.4x————
Interest coverage22.4x−2.8x−1.5x−1.0x−0.4x
Current ratio2.1x1.1x0.4x0.2x0.4x
Quick ratio2.1x1.1x0.4x0.2x0.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, billions

Projections

Project Agenus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Agenus says to expect

  • Cash: funding of planned operationsBased on the current operating plan, the upfront proceeds are expected to support ROBBIN initiation, regulatory activities and operations through the third quarter of 2027. Assuming full exercise of the warrants, the financing is expected to support the planned ROBBIN program and company operations through year-end 2031.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Agenus reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 92 of 93 of 9
Rule of 40−90.3%−187.4%−57.2%
Altman Z''−27.06−40.73−38.05
Accruals ratio−9.1%−27.4%32.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsPassFailPass
F-score3 of 92 of 93 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Agenus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
AgenusFY2510.4%−17.7%−67.6%——3
ImmunityBioFY25668.3%−226.0%−272.6%——3Compare
Century TherapeuticsFY251,556.8%−15.8%−95.9%———Compare
Atara BiotherapeuticsFY25−6.3%29.7%−42.2%———Compare
Monte Rosa TherapeuticsFY2563.5%−43.8%−22.2%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue2343371508829698156104114
Revenue growth−9.0%90.0%−14.2%307.9%−41.2%235.3%−66.8%59.5%−33.8%10.4%
Gross profit————8629288153103113
Research and development9511612516814317918723515679
Operating income−108−104−124−70−11726−179−160−120−20
Net income−127−121−162−112−183−29−231−257−232−3
Diluted EPS (US$)−0.03−0.02−0.03−0.02−0.02−0.00−15.64−13.75−10.590.00
Diluted shares (millions)4,3544,9215,5396,7498,6251114182230
Cash flow
Cash from operations−80−94−131−19−13910−175−224−158−77
Capital expenditure12345434531010
Free cash flow−92−97−135−23−143−24−228−234−159−77
Dividends paid0000000000
Share buybacks0000000100
Acquisitions0000103000
Stock-based compensation1312810102018231714
Balance sheet at fiscal year end
Cash and short-term investments7660536210030719376403
Debt incl. finance leases1311631314201413133845
Total assets157138136155214466414314226227
Total liabilities196214311387426418468462533505
Shareholders' equity−39−76−172−225−20434−61−160−326−271
Margins and ratios
Gross margin————97.3%98.8%89.2%98.0%99.5%99.1%
Operating margin−476.1%−242.1%−336.6%−46.7%−133.0%8.7%−183.0%−102.1%−116.4%−17.7%
Net margin−562.6%−281.5%−440.5%−74.3%−207.4%−9.7%−235.3%−164.7%−224.5%−2.7%
Free cash flow margin−409.7%−227.0%−366.2%−15.6%−161.7%−8.0%−233.0%−149.8%−153.6%−67.6%
Rule of 40 (growth + FCF margin)−418.7%−137.1%−380.4%292.4%−202.9%227.3%−299.9%−90.3%−187.4%−57.2%
Return on capital—−388.9%————————
Return on equity−803.7%—————————
Return on assets−63.6%−81.7%−117.9%−76.5%−98.9%−8.4%−52.5%−70.8%−86.0%−1.4%
Net debt to EBITDA—————−9.0x————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Agenus' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Agenus.